⌘K
t
Fusion Antibodies plc was informed on 8 May 2026 that, following a share purchase on 5 May 2026, Simon Peace holds 4,121,744 ordinary shares of 4 pence each. This holding represents approximately 3.30% of the Company's issued share capital.
| Date | 11 May 2026 |
| Time | 15:06:28 |
| Category | Holding(s) in company |
| ID | 8474D |
11 May 2026
Fusion Antibodies plc
("Fusion" or the "Company")
Holdings in Company
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, was informed on 8 May 2026 that, following a purchase of shares on 5 May 2026, Simon Peace holds 4,121,744 ordinary shares of 4 pence each in the Company, representing approximately 3.30 per cent. of the Company's issued share capital.
Enquiries:
|
Fusion Antibodies plc |
www.fusionantibodies.com |
|
Adrian Kinkaid, Chief Executive Officer Stephen Smyth, Chief Financial Officer |
Via Walbrook PR |
|
|
|
|
Allenby Capital Limited |
Tel: +44 (0)20 3328 5656 |
|
James Reeve/Vivek Bhardwaj (Corporate Finance) Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking) |
|
|
|
|
|
|
|
|
Shard Capital Partners LLP |
|
|
Damon Heath (Joint Broker) |
Tel: +44 (0)207 186 9952 |
|
|
|
|
|
|
|
Walbrook PR |
Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com |
|
Anna Dunphy |
Mob: +44 (0)7876 741 001 |
Investor Hub
We encourage all investors to share questions on this announcement via our investor hub https://investorhub.fusionantibodies.com/link/rJaa9e
About Fusion Antibodies plc
Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.
The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and/or expressed over 750 antibodies and successfully completed over 250 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.
The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.
Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.